Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 74

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 74
---
,300 $57,268 $10,032 17.5 %Europe33,526 21,098 12,428 58.9 %International2,867 1,882 985 52.3 %Revenue from sale of therapies, net$103,693 $80,248 $23,445 29.2 %

For the three months ended September 30, 2025, we generated net revenue from sale of therapies of $103.7 million due to the sale of KIMMTRAK, of which $67.3 million was in the United States, $33.5 million in Europe and $2.9 million in International. Revenue from sale of therapies, net increased in the three months ended September 30, 2025 compared to the three months ended September 30, 2024, due primarily to increased sales volume in the United States and Europe as well as global country expansion. 

R&D Expenses

The following table summarizes our R&D expenses (in thousands):

Three Months Ended September 30,20252024Increase / (decrease)% Increase / (decrease)External R&D expenses:PRAME programs$21,967 $18,512 $3,455 18.7 %Tebentafusp programs11,789 8,315 3,474 41.8 %Infectious disease programs1,347 1,324 23 1.7 %All other external clinical and preclinical costs15,551 6,361 9,190 144.5 %Total external R&D expenses50,654 34,512 16,142 46.8 %Internal R&D expenses:Salaries and other employee-related costs11,932 11,272 660 5.9 %Share-based compensation expense2,168 1,819 349 19.2 %All other internal R&D costs8,055 7,235 820 11.3 %U.K. R&D tax credits(2,237)(2,068)(169)8.2 %Total internal R&D expenses19,918 18,258 1,660 9.1 %Total R&D expenses$70,572 $52,770 $17,802 33.7 %

For the three months ended September 30, 2025, our R&D expenses were $70